Evidence map›Paper›PMID 39824988›Full record

ArticleScientific reports2025

Biochemical failure-free survival of

Marco M E Vogel, Isabel Rauscher, Jürgen E Gschwend, Türkay Hekimsoy, Nicola Gabler, Charlotte Olufs, Calogero D'Alessandria, Jan C Peeken, Stephanie E Combs, Matthias Eiber

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. An intra-patient contemporaneous comparison ofEuropean journal of nuclear medicine and molecular imaging · 2026
    Trial
  2. Comparison of twoEJNMMI radiopharmacy and chemistry · 2026
    Article
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Marco M E VogelDepartment of Radiation Oncology, TUM University Hospital rechts der Isar, TUM School of Medicine and Health, Technical University of Munich (TUM), Munich, Germany. marco.vogel@tum.de.
Isabel RauscherDepartment of Nuclear Medicine, TUM University Hospital rechts der Isar, TUM School of Medicine and Health, Technical University of Munich (TUM), Munich, Germany.
Jürgen E GschwendDepartment of Urology, TUM University Hospital rechts der Isar, TUM School of Medicine and Health, Technical University of Munich (TUM), Munich, Germany.
Türkay HekimsoyDepartment of Nuclear Medicine, TUM University Hospital rechts der Isar, TUM School of Medicine and Health, Technical University of Munich (TUM), Munich, Germany.
Nicola GablerDepartment of Nuclear Medicine, TUM University Hospital rechts der Isar, TUM School of Medicine and Health, Technical University of Munich (TUM), Munich, Germany.
Charlotte OlufsDepartment of Nuclear Medicine, TUM University Hospital rechts der Isar, TUM School of Medicine and Health, Technical University of Munich (TUM), Munich, Germany.
Calogero D'AlessandriaDepartment of Nuclear Medicine, TUM University Hospital rechts der Isar, TUM School of Medicine and Health, Technical University of Munich (TUM), Munich, Germany.
Jan C PeekenDepartment of Radiation Oncology, TUM University Hospital rechts der Isar, TUM School of Medicine and Health, Technical University of Munich (TUM), Munich, Germany.
Stephanie E CombsDepartment of Radiation Oncology, TUM University Hospital rechts der Isar, TUM School of Medicine and Health, Technical University of Munich (TUM), Munich, Germany.
Matthias EiberDepartment of Nuclear Medicine, TUM University Hospital rechts der Isar, TUM School of Medicine and Health, Technical University of Munich (TUM), Munich, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Prostate-specific membrane antigen (PSMA)-targeted positron emission tomography (PET) has improved localization of prostate cancer (PC) lesions in biochemical recurrence (BCR) for salvage radiotherapy (SRT). We conducted a retrospective review of patients undergoing

Indexed as

Neoplasm Recurrence, LocalPositron-Emission TomographyProstatic NeoplasmsRadiotherapy, Image-GuidedSalvage TherapyAgedAntigens, SurfaceDisease-Free SurvivalFluorine RadioisotopesGlutamate Carboxypeptidase IIHumansMaleMiddle AgedProstate-Specific AntigenRetrospective StudiesAntigens, SurfaceFluorine RadioisotopesFOLH1 protein, humanGlutamate Carboxypeptidase IIProstate-Specific Antigen18F-flotufolastat18F-rhPSMA-7Prostate cancerPSMA-PETSalvage radiotherapy

Identifiers

PMID39824988
PMCPMC11748678

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.